Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype
ENZY  
SEK  %
Logotype

Media

Press releases

2025

March 6, 2025 - Non-regulatory press release
Replay Link to Digital Press Briefing – March 5, 2025
February 28, 2025 - Non-regulatory press release
Invitation to Press Briefing – 5 March 2025
February 28, 2025 - Regulatory press release
New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms
February 18, 2025 - Regulatory press release
Year-end report 2024: Strong performance in core markets – preparing for international growth
January 9, 2025 - Non-regulatory press release
Enzymatica focuses on growth with new recruitment – Anna Söderlund joins as Senior Director Marketing & Sales

2024

November 7, 2024 - Regulatory press release
Interim report Q3/2024: Focus on developing existing and new markets
September 12, 2024 - Regulatory press release
Enzymatica announces outcome of new rights issue
September 9, 2024 - Regulatory press release
Enzymatica publishes supplementary prospectus
September 5, 2024 - Regulatory press release
Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load
August 26, 2024 - Regulatory press release
Publication of prospectus regarding Enzymatica’s rights issue
August 16, 2024 - Regulatory press release
Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.
August 6, 2024 - Regulatory press release
Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024
July 18, 2024 - Regulatory press release
Interim report Q2/2024: Enzymatica builds momentum for expansion
July 18, 2024 - Regulatory press release
Enzymatica's Board of Directors updates the financial targets
July 18, 2024 - Regulatory press release
Notice of Extraordinary General Meeting in Enzymatica AB (publ)
July 18, 2024 - Regulatory press release
Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million
June 13, 2024 - Regulatory press release
Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
May 7, 2024 - Regulatory press release
Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024
April 25, 2024 - Regulatory press release
Interim report Q1/2024: MDR certification opens up great commercial opportunities
April 9, 2024 - Regulatory press release
Enzymatica publishes annual report for 2023
Load more